Neuroscience Trials Australia
๐ฆ๐บAustralia
- Country
- ๐ฆ๐บAustralia
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
Phase 2
Terminated
- Conditions
- Ischemic Stroke
- Interventions
- Genetic: intravenous tissue plasminogen activator (tPA)Device: Intra-arterial Clot Retrieval with Solitaire device
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Neuroscience Trials Australia
- Target Recruit Count
- 70
- Registration Number
- NCT01492725
- Locations
- ๐ฆ๐บ
Austin Hospital, Melbourne, Victoria, Australia
๐ฆ๐บJohn Hunter Hospital, New Lambton Heights, New South Wales, Australia
๐ฆ๐บRoyal North Shore Hospital, St Leonards, New South Wales, Australia
Extending the Time for Thrombolysis in Emergency Neurological Deficits
Phase 3
Completed
- Conditions
- Stroke
- Interventions
- Drug: Tissue Plasminogen Activator (Alteplase)Drug: Placebo
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Neuroscience Trials Australia
- Target Recruit Count
- 180
- Registration Number
- NCT00887328
- Locations
- ๐ฆ๐บ
Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
๐ฆ๐บSt. Vincent's Hospital, Sydney, New South Wales, Australia
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath